T1	intervention 32 52	sentinel node biopsy
T2	control 60 87	standard axillary treatment
T3	eligibility 426 487	patients with clinically node-negative invasive breast cancer
T6	total-participants 701 705	1031
T7	intervention-participants 781 784	515
T8	control-participants 820 823	516
T9	outcome 1737 1779	quality of life and arm functioning scores
T14	iv-bin-percent 1363 1365	5%
T15	cv-bin-percent 1373 1376	13%
T18	iv-bin-percent 1427 1430	11%
T19	cv-bin-percent 1438 1441	31%
T5	outcome 1937 1951	anxiety levels
T11	outcome 1153 1167	any lymphedema
T12	outcome 1172 1184	sensory loss
T13	outcome 1278 1290	at 12 months
T10	outcome 1458 1469	Drain usage
T16	outcome 1471 1494	length of hospital stay
T17	outcome 1500 1550	time to resumption of normal day-to-day activities
T4	outcome-Measure 617 643	arm and shoulder morbidity
T20	outcome-Measure 648 663	quality of life
